Belgian Cancer Registry Data Application Form

The main task of the Belgian Cancer Registry (BCR) is the registration of all new cancer cases in Belgium. The database can be considered complete for Belgium since 2004.

To access BCR data, the approval of a data application is required. All applications are reviewed by the Internal Review Board. BCR will use the information provided in your application to determine the acceptability and feasibility of your data request. Please complete all relevant fields in this application form before submitting.

1. **APPLICANT DETAILS**

The personal data provided here will only be used or disclosed to communicate about this application form.

**A.1 Principal Investigator details**

Provide details of the individual leading the project, responsible for its management, outputs and dissemination of the results. This individual, commonly referred to as the promoter, usually serves as the primary contact for any formal correspondence. Details about the researcher conducting the research on a day-to-day basis should be outlined in Section A.3 below.

1. Name Click or tap here to enter text
2. Title/Role Click or tap here to enter text
3. Professional email address Click or tap here to enter text

**A.2 Applicant organization**

Provide the identity and contact details of the substantive organization of the Principal Investigator.

1. Organization name Click or tap here to enter text
2. Department Click or tap here to enter text
3. Address Click or tap here to enter text

**A.3 Details of the individual conducting the research**

Provide the identity and contact details of the individual who will conduct the research project.

1. Name Click or tap here to enter text
2. Title/Role Click or tap here to enter text
3. Professional email address Click or tap here to enter text

**A.4 Details of the individuals needing access to the data**

Access to our data requires a signed research agreement. Upon agreement, we will request the mobile phone number and professional email address of individuals seeking access. This information is necessary as the BCR data will be accessible within a secured environment, requiring a multi-factor authenticator on your mobile device. The QR code for activation of the authenticator will be sent to your professional email address.

1. **FUNDING ARRANGEMENTS**

BCR applies fixed rates per working day and a flat-rate cost contribution. Access to pseudonymized data at the record level incurs a flat-rate cost contribution of €4100, subject to yearly indexation. This contribution covers meetings for project initiation, methodological refinement, feedback on research protocols and data variables, data preparation, and secure data provision within BCR's environment. Linking procedures with partners are not included (see point C.4). Additional costs may arise based on expert support and data complexity, potentially increasing the number of working days required. Once the research protocol is finalized, a cost estimate will be provided.

Adequate funding available

[ ]  Yes

[ ]  No

1. **PROJECT**

Provide a short description of the project (can be bullet points). If available, accompany this application by a (detailed) research protocol.

1. Project title

Click or tap here to enter text

1. Describe the main hypothesis and specific research question of this project.

Click or tap here to enter text

1. Explain the methods you will use in this project, such as how you will analyze the data and how you will draw conclusions. BCR provides access to R and/or SAS for statistical analysis. Which of these statistical program(s) do you plan to use for your analyses? Additionally, do you require statistical guidance from BCR? (Subject to additional funding)

Click or tap here to enter text

1. If this project involves data linkage with other partners, specify the type of collaboration.

*For instance, coupling with the* [*International Mutualistic Agency (IMA)*](https://metadata.ima-aim.be/nl/app/bdds/Gz) *for treatment data / coupling with the* [*Crossroads Bank for Social security*](https://www.ksz-bcss.fgov.be/nl/gegevensbescherming/gegevens-en-dienstencatalogus-sociale-sector) *(CBS) for socio-economical data / …*

Click or tap here to enter text

1. Specify any intended outputs that will communicate the findings of this project with relevant audiences.

Select

Where other, provide further details of intended outputs: Click or tap here to enter text

1. Project timeline

Provide details of the anticipated project timeline (start date/end date of the project or research period, project duration, deadline submission thesis, ...). Has the project been submitted to an ethics committee, or does it already have ethical approval?

Click or tap here to enter text

1. **SUMMARY OF DATA REQUIREMENTS**

Provide here the desired selection criteria for your data request, if already known. This does not yet determine the final selection but helps us to properly prepare the data request.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| month |  year | until | month |  year |

1. Incidence years

*Cancer-related and treatment data are typically available at BCR 2 to 3 years post-diagnosis. For example, for incidence year 2022, cancer-related data are accessible from July 2024 onwards, and treatment-related data from March 2025 onwards.*

1. Cancer type(s)

*For all subcategories, refer to Annex 1.*

|  |  |  |
| --- | --- | --- |
| [ ]  Bone and soft tissue | [ ]  Eye and adnexa | [ ]  Male genital organs |
| [ ]  Breast | [ ]  Female genital organs | [ ]  Skin (excl. basal cell carcinoma) |
| [ ]  Central nervous system | [ ]  Head and neck | [ ]  Thorax  |
| [ ]  Digestive system | [ ]  Hematolymphoid system | [ ]  Urinary system |
| [ ]  Endocrine glands | [ ]  Ill-defined or unknown primary site | [ ]  Other, specify To code(s) |

1. Tumor localizations Topography code(s)
[*ICD-O-3 topography codes*](https://kankerregister.org/sites/default/files/2024-03/prplicdonl_nl.pdf)
2. Morphology tumor cell type + behavior

[*ICD-O-3 morphology codes*](https://kankerregister.org/sites/default/files/2024-03/prplicdonl_nl.pdf) *(f.i. adenocarcinoma: 8140/3)*

1. Stage, if applicable Click or tap here to enter text

*Clinical or pathological stage according to the Classification of Malignant Tumours (TNM).*

1. Sex [ ]  Male [ ]  Female [ ]  Both
2. Age ranges Lower limit until Upper limit
3. Treatment modalities of interest (including corresponding [nomenclature](https://webappsa.riziv-inami.fgov.be/Nomen/nl/search) and/or [ATC codes](https://atcddd.fhi.no/atc_ddd_index/)) + timing of treatment.
*We have treatment data available until maximally 5 years after incidence.*

Click or tap here to enter text

1. How do you want to receive the data? [ ]  Aggregated [ ]  Record level
*Aggregated: individual data combined in a summary form / Record level: individual data per patient or tumor (on BCR remote environment).*
2. Other variable(s): specify. Click or tap here to enter text
3. **ANY ADDITIONAL INFORMATION**

This section allows you the opportunity to share any other relevant information with BCR.

*Click or tap here to enter text*

**ANNEX 1**

Cancer types:

[ ]  Bone and soft tissue

[ ]  Bone

[ ]  Soft tissue

[ ]  Peritoneum and retroperitoneum

[ ]  Kaposi sarcoma

[ ]  Breast

[ ]  Central nervous system

[ ]  Meninges

[ ]  Brain

[ ]  Spinal cord, cranial nerves and CNS NOS

[ ]  Digestive system

[ ]  Oesophagus

[ ]  Oesophagus, squamous cell carcinoma

[ ]  Oesophagus, adenocarcinoma

[ ]  Oesophagus, other and NOS

[ ]  Cardia

[ ]  Stomach (excl. cardia)

[ ]  Small intestine

[ ]  Colon and rectum

[ ]  Colon

[ ]  Rectum

[ ]  Anus and anal canal

[ ]  Liver

[ ]  Liver, hepatocellular carcinoma

[ ]  Liver, cholangiocarcinoma

[ ]  Liver, other and NOS

[ ]  Gallbladder

[ ]  Biliary tract

[ ]  Pancreas

[ ]  Digestive system, NOS

[ ]  Endocrine glands

[ ]  Thyroid

[ ]  Thyroid, papillary carcinoma

[ ]  Thyroid, follicular carcinoma

[ ]  Thyroid, medullary carcinoma

[ ]  Thyroid, anaplastic carcinoma

[ ]  Thyroid, other and NOS (incl. mixed forms)

[ ]  Adrenal gland

[ ]  Endocrine glands, other and NOS

[ ]  Eye and adnexa

[ ]  Female genital organs

[ ]  Vulva

[ ]  Vagina

[ ]  Cervix uteri

[ ]  Corpus uteri

[ ]  Uterus, NOS

[ ]  Ovary

[ ]  Female genital organs, other and NOS

[ ]  Placenta

[ ]  Head and neck

[ ]  Lip

[ ]  Oral cavity

[ ]  Tongue

[ ]  Gum

[ ]  Floor of mouth

[ ]  Hard palate

[ ]  Mouth, NOS

[ ]  Oropharynx

[ ]  Base of tongue

[ ]  Soft palate, uvula and palate NOS

[ ]  Tonsil

[ ]  Oropharynx, other and NOS

[ ]  Hypopharynx

[ ]  Pyriform sinus

[ ]  Hypopharynx, other and NOS

[ ]  Nasopharynx

[ ]  Salivary glands

[ ]  Parotid gland

[ ]  Salivary glands, NOS

[ ]  Lip, oral cavity and pharynx, NOS

[ ]  Nasal cavity and paranasal sinuses

[ ]  Nasal cavity

[ ]  Paranasal sinuses

[ ]  Larynx

[ ]  Glottis

[ ]  Supraglottis

[ ]  Larynx other and NOS

[ ]  Hematolymphoid system

[ ]  Hodgkin lymphoma

[ ]  Mature B-cell non-Hodgkin lymphoma/leukaemia

[ ]  B-cell chronic lymphocytic leukaemia / small lymphocytic lymphoma

[ ]  Hairy cell leukaemia

[ ]  Other Mature B-cell leukaemia and related lymphoma

[ ]  Immunoproliferative disease

[ ]  Plasma cell neoplasm

[ ]  Marginal zone lymphoma

[ ]  Follicular lymphoma and related lymphoma

[ ]  Mantle cell lymphoma

[ ]  Diffuse large B-cell lymphoma and related large B-cell lymphoma

[ ]  Burkitt lymphoma / leukaemia

[ ]  Mature T-/NK- cell lymphoma

[ ]  Primary cutaneous T-cell lymphoma

[ ]  Peripheral NK/T-cell lymphoma

[ ]  Precursor neoplasm

[ ]  Precursor lymphoid neoplasm or acute lymphoblastic leukaemia / lymphoma

[ ]  Acute myeloid leukaemia and related precursor neoplasms

[ ]  Chronic myeloid neoplasm

[ ]  Chronic myeloid leukaemia

[ ]  Polycythaemia vera

[ ]  Primary myelofibrosis

[ ]  Essential thrombocythaemia

[ ]  Other MPN and related neoplasm

[ ]  Mast cell neoplasm

[ ]  Myelodysplastic syndrome

[ ]  Myelodysplastic/myeloproliferative neoplasm

[ ]  Histiocytic and dendritic cell neoplasm

[ ]  Unspecified haematological malignancy

[ ]  Ill-defined or unkown primary site

[ ]  Ill-defined primary site

[ ]  Unknown primary site

[ ]  Male genital organs

[ ]  Penis

[ ]  Prostate

[ ]  Testis

[ ]  Male genital organs, NOS

[ ]  Skin (excl. basal cell carcinoma)

[ ]  Melanoma

[ ]  Non-melanoma skin cancer (excl. basal cell carcinoma)

[ ]  Non-melanoma skin cancer, squamous cell carcinoma

[ ]  Non-melanoma skin cancer, other and NOS (excl. basal cell carcinoma)

[ ]  Thorax

[ ]  Trachea

[ ]  Lung

[ ]  Lung, SCLC

[ ]  Lung, NSCLC

[ ]  Lung, NSCL (squamous cell carcinoma)

[ ]  Lung, NSCLC (adenocarcinoma)

[ ]  Lung, NSCLC (other and NOS)

[ ]  Lung, other and NOS

[ ]  Mesothelioma

[ ]  Thymus

[ ]  Heart, mediastinum and pleura

[ ]  Respiratory system and intrathoracic organs, NOS

[ ]  Urinary system

[ ]  Kidney

[ ]  Renal pelvis

[ ]  Ureter

[ ]  Bladder

[ ]  Urinary organs, NOS